^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SL-172154

    i
    Associations
    News

    Trials

    Company:
    Shattuck
    Drug class:
    CD47 inhibitor, CD40 agonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (SL03-OHD-104) (NCT05275439)
    Phase 1
    Shattuck Labs, Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    03/17/2022
    Primary completion :
    02/06/2025
    Completion :
    02/06/2025
    TP53
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • SL-172154
    Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (SL03-OHD-105) (NCT05483933)
    Phase 1
    Shattuck Labs, Inc.
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    08/18/2022
    Primary completion :
    02/07/2025
    Completion :
    02/07/2025
    FOLR1
    |
    FOLR1 expression
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer (SL03-OHD-101) (NCT04406623)
    Phase 1
    Shattuck Labs, Inc.
    Completed
    Last update posted :
    01/30/2025
    Initiation :
    06/29/2020
    Primary completion :
    02/02/2023
    Completion :
    02/02/2023
    HRD
    |
    HRD
    |
    SL-172154